- ICH GCP
- Registro de ensayos clínicos de EE. UU.
- Ensayo clínico NCT07288086
Fiabilidad y Eficacia del Nuevo Sistema de Lente Intraocular y Cartucho Precargado Enova
Evaluation of the safety and efficacy of the new Enova® preloaded monofocal intraocular lens and cartridge injector system in cataract surgery
Descripción general del estudio
Estado
Condiciones
Intervención / Tratamiento
Descripción detallada
In this prospective and single-center clinical study, the safety and efficacy of the Enova PGF3 intraocular lens (IOL) and cartridge injector system will be evaluated.
The Enova PGF3 cartridge injector system is designed to be used in cataract surgeries. Cataract patients aged 40 years and older, both male and female, without any serious ocular disease other than cataracts, will undergo IOL implantation following cataract surgery. It is planned to perform a total of 200 implantations with either unilateral or bilateral implantation of the participants' eyes.
Postoperative visual acuity, refraction, patient satisfaction, and adverse events will be monitored during follow-up visits at day 1, week 1, and month 1.
The primary objectives of the study are to achieve an uncorrected distance visual acuity of 20/20 or better, and to maintain an error and complication rate related to the preloaded system below 7.5%. Secondary objectives include evaluating patient satisfaction and assessing whether surgeons find the preloaded system easy to use and if it meets their expectations.
The primary endpoints are refractive stability within ±0.50 D, uncorrected distance visual acuity of 20/20 or better, and a general clinical performance rating of the preloaded system with a score of 95% or higher. Secondary endpoints include the duration of surgery, accuracy of lens positioning, surgical complications, surgeon-reported ease of use, and patient satisfaction survey results meeting expectations.
As a safety parameter, adverse events reported in postoperative surgical reports will be evaluated.
Tipo de estudio
Inscripción (Actual)
Fase
- No aplica
Contactos y Ubicaciones
Ubicaciones de estudio
-
-
Fatih
-
Istanbul, Fatih, Turquía (Türkiye), 34250
- Istanbul University Istanbul Medical Faculty Ophthalmology Department
-
-
Criterios de participación
Criterio de elegibilidad
Edades elegibles para estudiar
Acepta Voluntarios Saludables
Géneros elegibles para el estudio
Descripción
Inclusion Criteria:
- Adults of either sex.
Age 40 years or older.
Willing and able to provide written informed consent and comply with planned study visits and procedures.
Healthy ocular status, with no ocular pathology other than cataract and mild refractive error.
Potential visual acuity of 20/32 (0.2 logMAR) or better in both eyes.
Presence of regular corneal astigmatism suitable for treatment with the study device.
Candidates for uncomplicated cataract surgery using the study device.
Exclusion Criteria:
- Irregular corneal astigmatism (e.g., keratoconus).
Corneal pathology (e.g., scar, dystrophy, pterygium, moderate to severe dry eye).
Monocular conditions (e.g., amblyopia).
Previous corneal surgery, including radial keratotomy, corneal refractive surgery, corneal transplantation, DSAEK, or lamellar keratoplasty.
Previous anterior or posterior segment surgery (e.g., vitrectomy, laser iridotomy).
Diabetic retinopathy.
Macular pathology (e.g., age-related macular degeneration [ARMD], epiretinal membrane [ERM]).
History of retinal detachment.
Surgical complications that may affect study outcomes, such as:
Decentration due to capsulorhexis issues
Improper lens placement
Inadequate or missing postoperative capsular support
Posterior capsular rupture
Vitreous loss
Iris damage (tear, rupture, etc.)
Acute or chronic ocular diseases known to affect visual acuity or study outcomes (e.g., immunosuppressed state, connective tissue disease, clinically significant atopic disease, diabetes, or other systemic or ocular conditions).
Participation in any investigational drug or device study within 30 days prior to study start, or ongoing participation in another study.
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Propósito principal: Tratamiento
- Asignación: N / A
- Modelo Intervencionista: Asignación de un solo grupo
- Enmascaramiento: Ninguno (etiqueta abierta)
Armas e Intervenciones
Grupo de participantes/brazo |
Intervención / Tratamiento |
|---|---|
|
Experimental: Patients who need cataract surgery
Participants will undergo standard cataract surgery using the new preloaded intraocular lens (IOL) system. The intervention involves implantation of the preloaded IOL following routine phacoemulsification techniques. |
This intervention uses a preloaded IOL delivery system, which allows for a single-use, sterile implantation during standard phacoemulsification cataract surgery. Unlike standard manually loaded IOLs, this system reduces preparation time and minimizes handling of the lens, potentially improving surgical efficiency and maintaining lens sterility. |
¿Qué mide el estudio?
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Uncorrected Distance Visual Acuity (UDVA) - Photopic Conditions
Periodo de tiempo: 1 month postoperatively
|
Proportion of eyes achieving 20/20 or better uncorrected distance visual acuity under photopic conditions. |
1 month postoperatively
|
|
Subjective Refractive Error
Periodo de tiempo: 1 month postoperatively
|
Eyes with a postoperative refractive error within ±0.50 diopters of the intended target. |
1 month postoperatively
|
|
Overall Clinical Performance of the Preloaded IOL System
Periodo de tiempo: 1 month after surgery
|
Surgeon-rated assessment of the general clinical performance of the preloaded system by The ENOVA PGF3 Questionnaire. This questionnaire is a 14-item, study-specific, non-validated survey developed to evaluate surgeons' experience with an intraocular lens (IOL) preloaded delivery system. Eleven items are rated on a 5-point Likert scale with the following scoring structure:
Some additional items are Yes/No questions and do not contribute to the numerical total score. The total numerical score is calculated by summing the 11 Likert-scaled items. Total score range: 11 to 55, with higher scores indicating better performance and more favorable user experience. |
1 month after surgery
|
Medidas de resultado secundarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Preloaded System Evaluation Patient Questionnaire
Periodo de tiempo: Baseline (preoperative) and 1 month postoperatively
|
Patient-reported outcomes assessing whether expectations for visual improvement and overall satisfaction were met.The questionnaire consists of 14 items assessing a patient's self-reported difficulty in performing vision-related daily activities. Each activity is rated using a 0-4 scale, where: 4 = No difficulty 3 = Mild difficulty 2 = Moderate difficulty 1 = Severe difficulty 0 = Unable to perform the activity The total score is calculated by summing responses across all 14 items. Total possible score range: 0 to 56 Higher scores indicate better visual function and less activity limitation. Lower scores indicate worse visual function. |
Baseline (preoperative) and 1 month postoperatively
|
|
Surgical Procedure Assessment
Periodo de tiempo: Intraoperative
|
Surgeon-reported ease of lens implantation and accuracy of lens placement, evaluating whether expectations for procedural handling were met.The surgeon notes, during the operative visit, the location of the incision, the size of the incision, whether the implantation system is compatible with the wound site, how many seconds the implantation time is shortened, and whether there were any issues with the unfolding of the intraocular lens or its placement into the capsular bag. |
Intraoperative
|
Otras medidas de resultado
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Serious Adverse Events
Periodo de tiempo: 1 month postoperatively
|
Any serious adverse events occurring during surgery or within 1 month after surgery. |
1 month postoperatively
|
|
Postoperative Inflammation
Periodo de tiempo: 1 week and 1 month postoperatively
|
Assessment of inflammation levels by biomicroscopic anterior chamber and vitreus examination according to Standardization of Uveitis Nomenclature (SUN) International Workshop Grading System |
1 week and 1 month postoperatively
|
|
Intraocular Pressure,
Periodo de tiempo: 1 week and 1 month postoperatively
|
Intraocular pressure is assessed via Goldmann Applanation Tonometry. Normal levels are accepted as 10-21 mmHG. |
1 week and 1 month postoperatively
|
Colaboradores e Investigadores
Patrocinador
Publicaciones y enlaces útiles
Publicaciones Generales
- Oshika T, Wolfe P. In vitro comparison of delivery performance of 4 preloaded intraocular lens injector systems for corneal and sclerocorneal incisions. J Cataract Refract Surg. 2019 Jun;45(6):840-846. doi: 10.1016/j.jcrs.2018.10.050. Epub 2019 Mar 8.
- Joshi RS. Comparative evaluation of an automated preloaded delivery system with a non-preloaded system. Indian J Ophthalmol. 2022 Dec;70(12):4307-4311. doi: 10.4103/ijo.IJO_1635_22.
- Acar B, Torun IM, Acar S. Evaluation of Preloaded IOL Delivery System and Hydrophobic Acrylic Intraocular Lens in Cataract Surgery. Open Ophthalmol J. 2018 Jun 14;12:94-103. doi: 10.2174/1874364101812010094. eCollection 2018.
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio (Actual)
Finalización primaria (Actual)
Finalización del estudio (Actual)
Fechas de registro del estudio
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Actual)
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Más información
Términos relacionados con este estudio
Palabras clave
Otros números de identificación del estudio
- IstanbulUni
Plan de datos de participantes individuales (IPD)
¿Planea compartir datos de participantes individuales (IPD)?
Descripción del plan IPD
Individual participant data will not be shared outside the study.
Información sobre medicamentos y dispositivos, documentos del estudio
Estudia un producto farmacéutico regulado por la FDA de EE. UU.
Estudia un producto de dispositivo regulado por la FDA de EE. UU.
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .